US Edition
Cell therapy anito-cel extends survival in treatment-resistant RRMM
Summary by rarecancernews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Cell therapy anito-cel extends survival in treatment-resistant RRMM
Nearly all the people with relapsed or refractory multiple myeloma (RRMM) who took part in a Phase 2 clinical trial responded to the cell therapy anitocabtagene autoleucel, or anito-cel, and are still alive a year after treatment. The findings will be reported in the oral presentation “Phase 2 Registrational Study of Anitocabtagene Autoleucel for Relapsed and/or Refractory Multiple Myeloma (RRMM): Updated Results from iMMagine-1,” at the Europea…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
